Livmarli 9.5 mg/ml
Livmarli 9.5 mg/ml is a medicine authorised by Swissmedic under authorisation number 69201. The authorisation holder is Mirum Pharmaceuticals AG. The medicinal product code is Synthetic medicines and the dispensing category is B: Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly. First authorisation was granted on 18 July 2024 and the authorisation is limited until 17 July 2029. ATC code A05AX04 places the medicine in the group Bile and liver therapy.
| Authorisation number | 69201 |
|---|---|
| Name | Livmarli 9.5 mg/ml |
| Full name | Livmarli 9.5 mg/ml, Lösung zum Einnehmen |
| Authorisation holder | Mirum Pharmaceuticals AG |
| Medicinal product code | Synthetic medicines |
| Dispensing category | B · Prescription only |
| ATC code | A05AX04 |
| First authorisation | 18 July 2024 |
| Authorisation validity | 17 July 2029 |
| No. | Name | Dispensing category | Authorisation date |
|---|---|---|---|
| 1 | Livmarli 9.5 mg/ml, Lösung zum Einnehmen | B | 18 July 2024 |
Scroll the table sideways
| Pack code | Quantity | Unit | ATC | IT code | Dispensing category |
|---|---|---|---|---|---|
| 1 | 30 | ml | A05AX04 | 04.99.0. | B |
Scroll the table sideways
Frequently asked questions
Is Livmarli 9.5 mg/ml authorised in Switzerland?
Yes. Livmarli 9.5 mg/ml is authorised by Swissmedic under authorisation number 69201, data as of 01 September 2026. The authorisation is limited until 17 July 2029.
Which dispensing category does Livmarli 9.5 mg/ml have?
Livmarli 9.5 mg/ml is in dispensing category B. Supplied only against a prescription which, at the prescriber's discretion, may be dispensed repeatedly.
Who is the authorisation holder of Livmarli 9.5 mg/ml?
The authorisation holder is Mirum Pharmaceuticals AG. The holder carries the legal responsibility for quality, safety and product information of the medicine in Switzerland.
Sources
Swissmedic data as of 01 September 2026. No medical advice. Independent directory, not affiliated with Swissmedic or the FOPH.